剂型改革对胶体果胶铋药效和安全性的影响研究

目的:观察胶体果胶铋分散片药效和安全性实验过程和结果分析,对照胶体果胶铋分散片与胶体果胶铋胶囊的药效和安全性的差异及剂型改革产生的影响。方法:随机抽取40例慢性胃炎患者的临床资料进行回顾性分析,根据治疗方法的不同,将其分为两组,对照组(20例)和观察组(20例),对照组采用胶体果胶铋胶囊,观察组采用胶体果胶铋分散片,针对两组治疗效果进行分析评价,深入探讨胶体果胶铋分散片剂型改革对药效和安全性的影响。结果:对照组治疗总有效率90.0%,观察组治疗总有效率为95.0%,两组患者在治疗效果差异不明显,不具有统计学意义,P>0.05,两组患者均无不良反应症状。结论:胶体果胶铋分散片具有消炎、止痛作用,药效良好,疗效确切,用药安全,值得临床推广与应用。

Objective： to observe the efficacy and safety of colloidal bismuth pectin dispersible tablets and analyze the results, and compare the difference of efficacy and safety between colloidal bismuth pectin dispersible tablets and colloidal bismuth pectin capsules and the effect of dosage form reform. Methods： the clinical data of 40 patients with chronic gastritis were analyzed retrospectively. According to the different treatment methods, they were divided into two groups： the control group （ n=20） and the observation group （ n=20）. The control group was treated with colloidal bismuth pectin capsule. In the observation group, colloidal bismuth pectin dispersible tablets were used to analyze and evaluate the therapeutic effects of the two groups, and the effects of dosage form reform on the efficacy and safety of colloidal bismuth pectin dispersible tablets were discussed in depth. Results： the total effective rate in the control group was 90.0 and the total effective rate in the observation group was 95.0%. There was no significant difference in the therapeutic effect between the two groups （ P〉0.05）. There were no adverse reaction symptoms in both groups. Conclusion： The colloidal pectin dispersible tablet has anti-inflammatory and analgesic effects, good efficacy, exact curative effect, and safe drug use, and is worthy of clinical promotion and application.